Cencora, Inc. (NYSE:COR) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. grew its position in Cencora, Inc. (NYSE:COR - Free Report) by 43.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 862,637 shares of the company's stock after acquiring an additional 262,823 shares during the quarter. American Century Companies Inc. owned 0.45% of Cencora worth $193,818,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of COR. JFS Wealth Advisors LLC boosted its holdings in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares during the period. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora during the fourth quarter valued at about $30,000. Kentucky Trust Co acquired a new stake in Cencora in the fourth quarter valued at approximately $33,000. Householder Group Estate & Retirement Specialist LLC grew its stake in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after buying an additional 69 shares during the last quarter. Finally, WASHINGTON TRUST Co increased its holdings in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Analyst Ratings Changes

COR has been the topic of several research analyst reports. Wells Fargo & Company boosted their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. increased their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Evercore ISI raised their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Finally, Mizuho began coverage on Cencora in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $280.20.

Remove Ads

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is currently owned by insiders.

Cencora Price Performance

Shares of NYSE COR traded up $2.94 during mid-day trading on Thursday, reaching $274.33. The company's stock had a trading volume of 1,015,455 shares, compared to its average volume of 1,379,449. The stock has a 50-day moving average of $252.47 and a two-hundred day moving average of $240.68. The stock has a market capitalization of $53.20 billion, a P/E ratio of 39.02, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $274.80.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.80%. Cencora's payout ratio is 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.